INGELHEIM, Germany--(BUSINESS WIRE) For media outside the US, the UK and Canada. Boehringer Ingelheim today announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD). These applications are based on data from the large Phase III TOviTO™ clinical trial programme. Further submissions in additional countries will be announced in due course.
Help employers find you! Check out all the jobs and post your resume.
